Myriad Genetics Inc (MYGN) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Myriad Genetics Inc

NASDAQ | MYGN

8.41

USD

-0.39 (-4.43%)

AT CLOSE (AS OF Apr 3, 2025)

$804M

MARKET CAP

P/E Ratio

-1.41

EPS

$29

52 Week High

$8.5

52 Week Low

LIFE SCIENCES

Sector

MYGN Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

MYGN Technicals

Tags:

MYGN Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$2.2M
Total Revenue	$745M
Cost Of Revenue	$748M
Costof Goods And Services Sold	$236M
Operating Income	-$257M
Selling General And Administrative	$573M
Research And Development	$89M
Operating Expenses	$844M
Investment Income Net	$2.5M
Net Interest Income	-$2.9M
Interest Income	$2.5M
Interest Expense	$2.9M
Non Interest Income	$748M
Other Non Operating Income	-$4.4M
Depreciation	$19M
Depreciation And Amortization	$62M
Income Before Tax	-$262M
Income Tax Expense	$1.1M
Interest And Debt Expense	$2.9M
Net Income From Continuing Operations	-$263M
Comprehensive Income Net Of Tax	-$258M
Ebit	-$259M
Ebitda	-$197M
Net Income	-$263M

Revenue & Profitability

Earnings Performance

MYGN Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Jun 30, 2024)

Field	Value (USD)
Total Assets	$1.1B
Total Current Assets	$292M
Cash And Cash Equivalents At Carrying Value	$92M
Cash And Short Term Investments	$97M
Inventory	$26M
Current Net Receivables	$118M
Total Non Current Assets	$794M
Property Plant Equipment	$116M
Accumulated Depreciation Amortization Ppe	$114M
Intangible Assets	$606M
Intangible Assets Excluding Goodwill	$320M
Goodwill	$286M
Investments	$9.8M
Long Term Investments	-
Short Term Investments	$4.9M
Other Current Assets	-
Other Non Current Assets	$15M
Total Liabilities	$345M
Total Current Liabilities	$149M
Current Accounts Payable	$33M
Deferred Revenue	-
Current Debt	-
Short Term Debt	-
Total Non Current Liabilities	$165M
Capital Lease Obligations	-
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	$39M
Short Long Term Debt Total	-
Other Current Liabilities	-
Other Non Current Liabilities	$35M
Total Shareholder Equity	$741M
Treasury Stock	-
Retained Earnings	-
Common Stock	$900K
Common Stock Shares Outstanding	$91M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	-$111M
Payments For Operating Activities	$3.3M
Proceeds From Operating Activities	$0
Change In Operating Liabilities	$24M
Change In Operating Assets	$13M
Depreciation Depletion And Amortization	$62M
Capital Expenditures	$73M
Change In Receivables	$13M
Change In Inventory	$1.8M
Profit Loss	-$263M
Cashflow From Investment	$32M
Cashflow From Financing	$153M
Proceeds From Repayments Of Short Term Debt	$40M
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$0
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$263M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$2.2M
Total Revenue	$745M
Cost Of Revenue	$748M
Costof Goods And Services Sold	$236M
Operating Income	-$257M
Selling General And Administrative	$573M
Research And Development	$89M
Operating Expenses	$844M
Investment Income Net	$2.5M
Net Interest Income	-$2.9M
Interest Income	$2.5M
Interest Expense	$2.9M
Non Interest Income	$748M
Other Non Operating Income	-$4.4M
Depreciation	$19M
Depreciation And Amortization	$62M
Income Before Tax	-$262M
Income Tax Expense	$1.1M
Interest And Debt Expense	$2.9M
Net Income From Continuing Operations	-$263M
Comprehensive Income Net Of Tax	-$258M
Ebit	-$259M
Ebitda	-$197M
Net Income	-$263M

Dividends

Field	Value
Ex Dividend Date	2009-06-15
Declaration Date	None
Record Date	None
Payment Date	None
Amount	1.75

MYGN Profile

Myriad Genetics Inc Profile

Sector: LIFE SCIENCES

Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	9.42%	-	742,693,504
NVDA	$101.80	-7.81%	$2.68T	334,149,797
INTC	$22.43	2.05%	$95.85B	240,924,655
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$5.99	1,796.17%	$26.40M	310,904
MKTW	$9.19	1,684.81%	$19.91M	117,875
MRM	$0.69	87.76%	$2.91M	53,662,982
PTIX	$0.42	84.14%	$4.04M	177,332,811
OSRH	$2.47	68.03%	$40.06M	89,471,971

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,865,554
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

MYGN $8.41 (-4.43%) Quote details